Wave Life Sciences to Present at Upcoming Investor Conferences
Rhea-AI Summary
Wave Life Sciences (Nasdaq: WVE) announced that President and CEO Paul Bolno will participate in analyst-led fireside chats at two August 2026 investor conferences: the BofA Securities 2026 SMID Cap Executive Insights Event on August 11 at 1:00 p.m. ET and the Canaccord Genuity 46th Annual Growth Conference on August 12 at 9:30 a.m. ET. Live webcasts and limited-time replays will be available via the Investor Events section of the company’s website.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in August.
BofA Securities 2026 SMID Cap Executive Insights Event
Date: Tuesday, August 11, 2026
Details: Paul Bolno, MD, MBA, President and CEO, will participate in an analyst-led fireside chat at 1:00 p.m. ET
Canaccord Genuity 46th Annual Growth Conference
Date: Wednesday, August 12, 2026
Details: Dr. Bolno will participate in an analyst-led fireside chat at 9:30 a.m. ET
Live webcasts of the presentations can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Replays of these presentations will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
